Remicade
Rx100 mg/20 ml • ইনট্রাভিট্রিয়াল ইনজেকশন
ইঙ্গিত ও ব্যবহার
Remicade এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Dosage Crohn’s Disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some adult patients who initially respond to treatment may benefit from increasing the dose to 10 mg/kg if they later lose their response.Pediatric Crohn’s Disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.Ulcerative Colitis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.Pediatric Ulcerative Colitis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.Rheumatoid Arthritis: In conjunction with methotrexate, 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some patients may benefit from increasing the dose up to 10mg/kg or treating as often as every 4 weeks.Ankylosing Spondylitis: 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks.Psoriatic Arthritis and Plaque Psoriasis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
পার্শ্বপ্রতিক্রিয়া
Most common adverse reactions (>10%)- infections (e.g. upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Serious infections- do not give Remsima during an active infection. If an infection develops, monitor carefully and stop Remsima if infection becomes serious.Invasive fungal infections- for patients who develop a systemic illness on Remsima, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemicMalignancies- the incidence of malignancies including lymphoma was greater in Remsima treated patients than in controls. Due to the risk of HSTCL carefully assess the risk/benefit especially if the patient has Crohn’s disease or ulcerative colitis, is male, and is receiving azathioprine or 6-mercaptopurine treatment.Hepatitis B virus reactivation- test for HBV infection before starting Remsima. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop Remsima and begin anti-viral therapy.Hepatotoxicity- rare severe hepatic reactions, some fatal ornecessitating liver transplantation. Stop Remsima in cases of jaundice and/or marked liver enzyme elevations.Heart failure- new onset or worsening symptoms may occur.Cytopenias- advise patients to seek immediate medical attention if signs and symptoms develop, and consider stopping Remsima.Hypersensitivity- serious infusion reactions including anaphylaxis or serum sickness-like reactions may occur. Demyelinating disease- exacerbation or new onset may occur.Lupus-like syndrome- stop Remsima if syndrome develops.Live vaccines or therapeutic infectious agents- should not be given with Remsima. Bring pediatric patients
নিষেধাজ্ঞা
Infliximab doses >5 mg/kg in moderate to severe heart failure. Previous severe hypersensitivity reaction to Infliximab or known hypersensitivity to inactive components of Infliximab or to any murine proteins.